Kadmon (KDMN) versus Cesca Therapeutics (NASDAQ:KOOL) Critical Analysis

Kadmon (NYSE: KDMN) and Cesca Therapeutics (NASDAQ:KOOL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Insider & Institutional Ownership

How to Become a New Pot Stock Millionaire

61.7% of Kadmon shares are owned by institutional investors. Comparatively, 2.6% of Cesca Therapeutics shares are owned by institutional investors. 8.4% of Kadmon shares are owned by company insiders. Comparatively, 3.9% of Cesca Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Kadmon and Cesca Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kadmon $12.26 million 27.26 -$79.77 million ($1.49) -2.85
Cesca Therapeutics $14.52 million 1.60 -$29.09 million ($0.45) -4.49

Cesca Therapeutics has higher revenue and earnings than Kadmon. Cesca Therapeutics is trading at a lower price-to-earnings ratio than Kadmon, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Kadmon and Cesca Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kadmon 1 0 3 0 2.50
Cesca Therapeutics 0 1 0 0 2.00

Kadmon presently has a consensus target price of $13.25, indicating a potential upside of 211.76%. Given Kadmon’s stronger consensus rating and higher possible upside, research analysts plainly believe Kadmon is more favorable than Cesca Therapeutics.

Profitability

This table compares Kadmon and Cesca Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kadmon -650.47% N/A -110.26%
Cesca Therapeutics -43.35% -17.76% -11.64%

Risk & Volatility

Kadmon has a beta of 5.59, indicating that its share price is 459% more volatile than the S&P 500. Comparatively, Cesca Therapeutics has a beta of -1.05, indicating that its share price is 205% less volatile than the S&P 500.

Summary

Kadmon beats Cesca Therapeutics on 9 of the 14 factors compared between the two stocks.

About Kadmon

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.

About Cesca Therapeutics

Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL
Ohtani Goes Deep in Third Straight Game for Angels
Ohtani Goes Deep in Third Straight Game for Angels


Leave a Reply

 
© 2006-2018 BBNS.